Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer

Patrick Loehrer, S. Rynard, R. Ansari, J. Songer, K. Pennington, Lawrence Einhorn

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

From December 1987 through April 1989, 40 patients with extensive-stage small cell carcinoma of the lung were enrolled in a Hoosier Oncology Group (HOG) trial using etoposide, ifosfamide, and cisplatin (VIP). Patients with extensive disease were eligible if they had not received prior chemotherapy, had a Karnofsky performance status of 50 or more, and had adequate renal function (creatinine, < 1.5 mg/dl) and bone marrow reserve (granulocyte count, ≥ 2500/μl; platelets, ≥ 125,000/μl). Doses of therapy were: etoposide 75 mg/m2/day on days 1 to 5, ifosfamide 1.2 g/m2/day on days 1 to 5, and cisplatin 20 mg/m2/day on days 1 to 5. The first 11 patients received a 5-day course; this was repeated every 21 days for four cycles, but therapy was shortened to 4 days when unacceptable toxicity was noticed in these patients. Overall, 14 (37%) had a complete remission (overall response rate, 71.1%) with a median survival of 42 weeks (28 weeks on 5-day regimen and 45 weeks on 4-day regimen). There were five early deaths. Although toxic, VIP produces a high complete remission rate in patients with extensive disease and warrants further evaluation. A prospective randomized trial comparing cisplatin and etoposide to the VIP regimen is underway through HOG.

Original languageEnglish
Pages (from-to)669-673
Number of pages5
JournalCancer
Volume69
Issue number3
StatePublished - 1992

Fingerprint

Ifosfamide
Small Cell Lung Carcinoma
Etoposide
Cisplatin
Karnofsky Performance Status
Poisons
Granulocytes
Creatinine
Blood Platelets
Bone Marrow
Kidney
Drug Therapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Loehrer, P., Rynard, S., Ansari, R., Songer, J., Pennington, K., & Einhorn, L. (1992). Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. Cancer, 69(3), 669-673.

Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. / Loehrer, Patrick; Rynard, S.; Ansari, R.; Songer, J.; Pennington, K.; Einhorn, Lawrence.

In: Cancer, Vol. 69, No. 3, 1992, p. 669-673.

Research output: Contribution to journalArticle

Loehrer, P, Rynard, S, Ansari, R, Songer, J, Pennington, K & Einhorn, L 1992, 'Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer', Cancer, vol. 69, no. 3, pp. 669-673.
Loehrer P, Rynard S, Ansari R, Songer J, Pennington K, Einhorn L. Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. Cancer. 1992;69(3):669-673.
Loehrer, Patrick ; Rynard, S. ; Ansari, R. ; Songer, J. ; Pennington, K. ; Einhorn, Lawrence. / Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. In: Cancer. 1992 ; Vol. 69, No. 3. pp. 669-673.
@article{c516d0fcc0924ac79783ae8475e5e943,
title = "Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer",
abstract = "From December 1987 through April 1989, 40 patients with extensive-stage small cell carcinoma of the lung were enrolled in a Hoosier Oncology Group (HOG) trial using etoposide, ifosfamide, and cisplatin (VIP). Patients with extensive disease were eligible if they had not received prior chemotherapy, had a Karnofsky performance status of 50 or more, and had adequate renal function (creatinine, < 1.5 mg/dl) and bone marrow reserve (granulocyte count, ≥ 2500/μl; platelets, ≥ 125,000/μl). Doses of therapy were: etoposide 75 mg/m2/day on days 1 to 5, ifosfamide 1.2 g/m2/day on days 1 to 5, and cisplatin 20 mg/m2/day on days 1 to 5. The first 11 patients received a 5-day course; this was repeated every 21 days for four cycles, but therapy was shortened to 4 days when unacceptable toxicity was noticed in these patients. Overall, 14 (37{\%}) had a complete remission (overall response rate, 71.1{\%}) with a median survival of 42 weeks (28 weeks on 5-day regimen and 45 weeks on 4-day regimen). There were five early deaths. Although toxic, VIP produces a high complete remission rate in patients with extensive disease and warrants further evaluation. A prospective randomized trial comparing cisplatin and etoposide to the VIP regimen is underway through HOG.",
author = "Patrick Loehrer and S. Rynard and R. Ansari and J. Songer and K. Pennington and Lawrence Einhorn",
year = "1992",
language = "English",
volume = "69",
pages = "669--673",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer

AU - Loehrer, Patrick

AU - Rynard, S.

AU - Ansari, R.

AU - Songer, J.

AU - Pennington, K.

AU - Einhorn, Lawrence

PY - 1992

Y1 - 1992

N2 - From December 1987 through April 1989, 40 patients with extensive-stage small cell carcinoma of the lung were enrolled in a Hoosier Oncology Group (HOG) trial using etoposide, ifosfamide, and cisplatin (VIP). Patients with extensive disease were eligible if they had not received prior chemotherapy, had a Karnofsky performance status of 50 or more, and had adequate renal function (creatinine, < 1.5 mg/dl) and bone marrow reserve (granulocyte count, ≥ 2500/μl; platelets, ≥ 125,000/μl). Doses of therapy were: etoposide 75 mg/m2/day on days 1 to 5, ifosfamide 1.2 g/m2/day on days 1 to 5, and cisplatin 20 mg/m2/day on days 1 to 5. The first 11 patients received a 5-day course; this was repeated every 21 days for four cycles, but therapy was shortened to 4 days when unacceptable toxicity was noticed in these patients. Overall, 14 (37%) had a complete remission (overall response rate, 71.1%) with a median survival of 42 weeks (28 weeks on 5-day regimen and 45 weeks on 4-day regimen). There were five early deaths. Although toxic, VIP produces a high complete remission rate in patients with extensive disease and warrants further evaluation. A prospective randomized trial comparing cisplatin and etoposide to the VIP regimen is underway through HOG.

AB - From December 1987 through April 1989, 40 patients with extensive-stage small cell carcinoma of the lung were enrolled in a Hoosier Oncology Group (HOG) trial using etoposide, ifosfamide, and cisplatin (VIP). Patients with extensive disease were eligible if they had not received prior chemotherapy, had a Karnofsky performance status of 50 or more, and had adequate renal function (creatinine, < 1.5 mg/dl) and bone marrow reserve (granulocyte count, ≥ 2500/μl; platelets, ≥ 125,000/μl). Doses of therapy were: etoposide 75 mg/m2/day on days 1 to 5, ifosfamide 1.2 g/m2/day on days 1 to 5, and cisplatin 20 mg/m2/day on days 1 to 5. The first 11 patients received a 5-day course; this was repeated every 21 days for four cycles, but therapy was shortened to 4 days when unacceptable toxicity was noticed in these patients. Overall, 14 (37%) had a complete remission (overall response rate, 71.1%) with a median survival of 42 weeks (28 weeks on 5-day regimen and 45 weeks on 4-day regimen). There were five early deaths. Although toxic, VIP produces a high complete remission rate in patients with extensive disease and warrants further evaluation. A prospective randomized trial comparing cisplatin and etoposide to the VIP regimen is underway through HOG.

UR - http://www.scopus.com/inward/record.url?scp=0026540950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026540950&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 669

EP - 673

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -